Tibau, A., Martínez, M. T., Ramos, M., Cruz-Merino, L., Santaballa, A., O'Connor, M., . . . Albanell Mestres, J. (2023). Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: Patient-reported outcomes from the FLIPPER trial.
Citación estilo ChicagoTibau, Ariadna, et al. Quality of Life With Palbociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Endocrine-sensitive Hormone Receptor-positive and HER2-negative Advanced Breast Cancer: Patient-reported Outcomes From the FLIPPER Trial. 2023.
Cita MLATibau, Ariadna, et al. Quality of Life With Palbociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Endocrine-sensitive Hormone Receptor-positive and HER2-negative Advanced Breast Cancer: Patient-reported Outcomes From the FLIPPER Trial. 2023.